- Home
- LFVN vs KPTI Comparison
LFVN vs KPTI Comparison
Compare LFVN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 172.6M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LFVN | KPTI |
|---|---|---|
| Price | $4.04 | $7.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.00 | ★ $14.67 |
| AVG Volume (30 Days) | 74.0K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.31% | N/A |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $22.00 | ★ N/A |
| Revenue Growth | ★ 1.86 | 0.57 |
| 52 Week Low | $3.90 | $3.65 |
| 52 Week High | $15.37 | $10.99 |
Technical Indicators
Market Signals| Indicator | LFVN | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 31.25 | 51.44 |
| Support Level | $3.99 | $5.53 |
| Resistance Level | $5.37 | $7.81 |
| Average True Range (ATR) | 0.22 | 0.78 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 1.18 | 52.72 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).